Study: T-1249 benefits those with resistance to Fuzeon
BY Advocate.com Editors
September 18 2003 12:00 AM ET
Study data presented Monday at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy show that Roche and Trimeris's second-generation experimental fusion inhibitor, T-1249, can reduce the HIV viral loads of patients who have developed resistance to the companies' first fusion inhibitor, Fuzeon. Data from a Phase I/II study of the experimental drug showed that it was effective in significantly reducing the viral loads of 73% of patients who developed resistance to Fuzeon. No serious drug-related side effects were reported by the study volunteers. "The results from this study of T-1249 demonstrate that fusion inhibitors constitute an expanding class of anti-HIV drugs with the potential to be used sequentially," said Dani Bolognesi, CEO at Trimeris. Next up are Phase II clinical trials, which will begin in 2004.
- EXCLUSIVE: Watch the Official Trailer for 54: The Director's Cut
- Why Can't We Talk About Homophobia in the Black Community?
- Op-ed: Let's Keep the Momentum Going After Win in Ireland
- WATCH: Out Musician Mika Shares Video for 'Good Guys,' a Bittersweet Homage to Gay Men
- San Diego Mourns Third Trans Teen to Die by Suicide
- Vatican Official Calls Irish Marriage Vote 'Defeat for Humanity'